Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, July 2019–February 2020

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Alleman, Mary M. ; Jorba, Jaume ; Greene, Sharon A. ; Diop, Ousmane M. ; Iber, Jane ; Tallis, Graham ; Goel, Ajay ; Wiesen, Eric ; Wassilak, Steven G.F. ; Burns, Cara C.
• Corporate Authors:
  Center for Global Health (U.S.)Global Immunization Division,. ; National Center for Immunization and Respiratory Diseases (U.S.)Division of Viral Diseases. ; Centers for Disease Control and Prevention (U.S.)Epidemic Intelligence Service. ; World Health Organization. Polio Eradication Department.
• Description:
  Circulating vaccine-derived polioViruses (cVDPVs) can emerge in areas with low polioVirus immunity and cause outbreaks* of paralytic polio (1-5). Among the three types of wild polioVirus, type 2 was declared eradicated in 2015 (1,2). The use of trivalent oral polioVirus vaccine (tOPV; types 1, 2, and 3 Sabin strains) ceased in April 2016 via a 1-month-long, global synchronized switch to bivalent OPV (bOPV; types 1 and 3 Sabin strains) in immunization activities (1-4). Monovalent type 2 OPV (mOPV2; type 2 Sabin strain) is available for cVDPV type 2 (cVDPV2) outbreak response immunization (1-5). The number and geographic breadth of post-switch cVDPV2 outbreaks have exceeded forecasts that trended toward zero outbreaks 4 years after the switch and assumed rapid and effective control of any that occurred (4). New cVDPV2 outbreaks have been seeded by mOPV2 use, by both suboptimal mOPV2 coverage within response zones and recently mOPV2-vaccinated children or contacts traveling outside of response zones, where children born after the global switch are fully susceptible to polioVirus type 2 Transmission (2-4). In addition, new emergences can develop by inadvertent exposure to Sabin OPV2-containing vaccine (i.e., residual response mOPV2 or tOPV) (4). This report updates the January 2018-June 2019 report with information on global cVDPV outbreaks during July 2019-February 2020 (as of March 25, 2020)| (2). Among 33 cVDPV outbreaks reported during July 2019-February 2020, 31 (94%) were cVDPV2; 18 (58%) of these followed new emergences. In mid-2020, the Global Polio Eradication Initiative (GPEI) plans to introduce a genetically stabilized, novel OPV type 2 (nOPV2) that has a lower risk for generating VDPV2 than does Sabin mOPV2; if nOPV2 is successful in limiting new VDPV2 emergences, GPEI foresees the replacement of Sabin mOPV2 with nOPV2 for cVDPV2 outbreak responses during 2021 (2,4,6).
• Subjects:
  Disease Outbreaks Full Report Global Health Humans Poliomyelitis PolioVirus PolioVirus Vaccine, Oral Serotyping
• Source:
  MMWR Morbidity Mortal Weekly Rep. 69(16):489-495
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  32324719
• Pubmed Central ID:
  PMC7188410
• Document Type:
  Journal Article
• Pages in Document:
  7 pdf pages
• Volume:
  69
• Issue:
  16
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:c8dcb27b4e8624d9ee387c97bb0cf3d842ac9bdb8f41d85c260e380df22c52e9500c14d66e1612e16a4a8576073762f2c519438d0e74a9bee1aff9b0b38504be
• Download URL:
  https://stacks.cdc.gov/view/cdc/87750/cdc_87750_DS1.pdf
• File Type:
  [PDF - 2.59 MB ]